ONT - Ticker AI Digest

Oxford Nanopore Technologies Ltd 📰 1
TradingFloor AI GO VIP Login

Digested News

Today's Catalysts (ONT) 1
ONT 15:01
Oxford Nanopore Technologies Ltd
Share Incentive Plan - Director/PDMR Shareholding
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
Under the SIP, the SIP Trustee will award each participating employee one Matching Share (as defined in the SIP) for each Ordinary Share <mark style="background-color:yellow">purchase</mark>d by the employee under the SIP. On 12 March 2026, the Company issued 121 Ordinary Shares to the SIP Trustee to hold on behalf of Nick Keher to satisfy the Matching Shares awarded under the SIP to him on that date.
AI 0
No items for this category on selected date.
Acquisitions 0
No items for this category on selected date.
Agreement 0
No items for this category on selected date.
Approvals 0
No items for this category on selected date.
Authorisation 0
No items for this category on selected date.
Awards 0
No items for this category on selected date.
BTC 0
No items for this category on selected date.
Blockchain 0
No items for this category on selected date.
Breakthrough 0
No items for this category on selected date.
BuyBack 0
No items for this category on selected date.
Cancellations 0
No items for this category on selected date.
CashOffer 0
No items for this category on selected date.
Collaborate 0
No items for this category on selected date.
ContractWin 0
No items for this category on selected date.
Covid-19 0
No items for this category on selected date.
Deals 0
No items for this category on selected date.
Diamond 0
No items for this category on selected date.
DirectorDealing 5
ONT 15:01
Oxford Nanopore Technologies Ltd
Share Incentive Plan - Director/PDMR Shareholding
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
Under the SIP, the SIP Trustee will award each participating employee one Matching Share (as defined in the SIP) for each Ordinary Share <mark style="background-color:yellow">purchase</mark>d by the employee under the SIP. On 12 March 2026, the Company issued 121 Ordinary Shares to the SIP Trustee to hold on behalf of Nick Keher to satisfy the Matching Shares awarded under the SIP to him on that date.
ONT 15:01
Oxford Nanopore Technologies Ltd
Issue of Equity; Director/PDMR Shareholding
ONT 15:01
Oxford Nanopore Technologies Ltd
Grant of LTIP awards; Director/PDMR Notification
ONT 06:01
Oxford Nanopore Technologies Ltd
Director/PDMR Shareholding
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
Duncan Tatton-Brown - <mark style="background-color:yellow">purchase</mark> of shares
ONT 15:01
Oxford Nanopore Technologies Ltd
Share Incentive Plan - Director/PDMR Shareholding
Discovery 0
No items for this category on selected date.
Exceeded 0
No items for this category on selected date.
FCA 0
No items for this category on selected date.
FDA 0
No items for this category on selected date.
Grants 0
No items for this category on selected date.
InvestmentPlan 0
No items for this category on selected date.
JV 0
No items for this category on selected date.
Launch 0
No items for this category on selected date.
Litigation 0
No items for this category on selected date.
NewContract 0
No items for this category on selected date.
Offers 0
No items for this category on selected date.
Offtake 0
No items for this category on selected date.
Orders 0
No items for this category on selected date.
Partner 0
No items for this category on selected date.
Patents 0
No items for this category on selected date.
Placing 0
No items for this category on selected date.
Positive 0
No items for this category on selected date.
Proposals 0
No items for this category on selected date.
Reports 0
No items for this category on selected date.
Results 1
ONT 06:01
Oxford Nanopore Technologies Ltd
Annual results for the year ended 31 December 2025
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
**Summary of Oxford Nanopore Technologies plc Annual Results for the Year Ended 31 December 2025**
Oxford Nanopore Technologies plc reported strong financial and operational performance for the year ended 31 December 2025, with significant revenue growth and progress toward profitability. Key highlights include
### **Financial Performance**
**Revenue Growth**Revenue increased by 24.2% on a constant currency basis to £223.9 million, slightly ahead of the top end of FY25 guidance. Growth was broad-based across all regions, products, and customer types.
**Regional Growth**EMEAI, APAC, and AMR regions grew by 26.3%, 23.2%, and 22.2% respectively on a constant currency basis.
**Customer Segments**: ClinicalBioPharmaApplied Industrialand Research segments grew by 59.9%30.4%27.2%and 15.1% respectively.
**Product Growth**PromethION product range led with 43.1% growth, while MinION and Other revenue grew by 2.4% and 12.0% respectively.
**Gross Margin**Increased by 110 basis points to 58.6%, driven by operational improvements and pricing model changes. Adjusted gross margin was 59.4%.
**Adjusted EBITDA**Loss improved to £(86.7) million from £(117.9) million in FY24, reflecting increased gross profits and cost control.
**Cash Position**The company remains well-capitalized with £302.8 million in cash, cash equivalents, and other liquid investments.
### **Operational and Strategic Highlights**
**Market Expansion**Strong demand across priority markets, particularly in Clinical, BioPharma, and Applied Industrial segments, driven by the adoption of Oxford Nanopores technology for richer, faster data.
**Clinical Collaborations**Strategic partnerships with Cepheid and bioMérieux to develop automated infectious disease sequencing solutions and rapid tuberculosis characterization.
**Technology Advancements**Improvements in throughput, cost efficiency, and robustness, particularly for the PromethION platform, alongside enhanced basecalling and real-time methylation detection.
**Scientific Validation**Over 4,000 peer-reviewed papers published in 2025, reinforcing scientific leadership and supporting clinical and commercial adoption.
**Strategic Focus**Refinement of the operating model to prioritize high-value market opportunities, resulting in restructuring actions to streamline the portfolio and concentrate investment.
**Leadership Transition**Francis Van Parys appointed as CEO, succeeding Gordon Sanghera, who will remain as an advisor until early 2027.
### **Outlook**
**FY26 Guidance**Revenue expected to grow by 21-25% on a constant currency basis, with growth weighted toward Applied end markets. Gross margin projected at approximately 62%.
**Medium-Term Goals**Reaffirmed commitment to reach adjusted EBITDA breakeven in FY27 and become cash flow positive in FY28, supported by <mark style="background-color:yellow">above</mark>-market revenue growth and operational improvements.
### **Key Challenges and Risks**
**Market Competition**Ongoing litigation with MGI over patent and trade secret infringements, with trials set for 2027.
**Regulatory Compliance**Continued efforts to strengthen quality systems and operational processes for deeper penetration of clinical and regulated markets.
**Economic Uncertainty**Potential impact of macroeconomic conditions, supply chain disruptions, and funding pressures in key markets.
### **Conclusion**
Oxford Nanopore Technologies plc demonstrated robust growth and strategic progress in 2025, positioning itself for sustained expansion in both research and applied markets. The company’s focus on innovation, operational efficiency, and strategic partnerships underscores its commitment to long-term value creation. With a strong balance sheet and clear medium-term goals, Oxford Nanopore is well-placed to capitalize on the growing demand for its molecular sensing technology.
Significant 0
No items for this category on selected date.
Speculation 0
No items for this category on selected date.
Strategic 0
No items for this category on selected date.
Suspension 0
No items for this category on selected date.
TR1 0
No items for this category on selected date.
Takeover 0
No items for this category on selected date.
Understanding 0
No items for this category on selected date.
Updates 1
ONT 14:01
Oxford Nanopore Technologies Ltd
Update on legal action against MGI Australia
Vaccine 0
No items for this category on selected date.
Wins 0
No items for this category on selected date.
Worth 0
No items for this category on selected date.
All Market News (Last 30 Days) 10
ONT 15:01
Oxford Nanopore Technologies Ltd
Share Incentive Plan - Director/PDMR Shareholding
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
Under the SIP, the SIP Trustee will award each participating employee one Matching Share (as defined in the SIP) for each Ordinary Share <mark style="background-color:yellow">purchase</mark>d by the employee under the SIP. On 12 March 2026, the Company issued 121 Ordinary Shares to the SIP Trustee to hold on behalf of Nick Keher to satisfy the Matching Shares awarded under the SIP to him on that date.
ONT 15:01
Oxford Nanopore Technologies Ltd
Issue of Equity; Director/PDMR Shareholding
ONT 06:01
Oxford Nanopore Technologies Ltd
Upcoming Investor Events and Conferences
ONT 15:01
Oxford Nanopore Technologies Ltd
Grant of LTIP awards; Director/PDMR Notification
ONT 06:01
Oxford Nanopore Technologies Ltd
Director/PDMR Shareholding
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
Duncan Tatton-Brown - <mark style="background-color:yellow">purchase</mark> of shares
ONT 15:01
Oxford Nanopore Technologies Ltd
Issue of Equity and Total Voting Rights
ONT 06:01
Oxford Nanopore Technologies Ltd
Annual results for the year ended 31 December 2025
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
**Summary of Oxford Nanopore Technologies plc Annual Results for the Year Ended 31 December 2025**
Oxford Nanopore Technologies plc reported strong financial and operational performance for the year ended 31 December 2025, with significant revenue growth and progress toward profitability. Key highlights include
### **Financial Performance**
**Revenue Growth**Revenue increased by 24.2% on a constant currency basis to £223.9 million, slightly ahead of the top end of FY25 guidance. Growth was broad-based across all regions, products, and customer types.
**Regional Growth**EMEAI, APAC, and AMR regions grew by 26.3%, 23.2%, and 22.2% respectively on a constant currency basis.
**Customer Segments**: ClinicalBioPharmaApplied Industrialand Research segments grew by 59.9%30.4%27.2%and 15.1% respectively.
**Product Growth**PromethION product range led with 43.1% growth, while MinION and Other revenue grew by 2.4% and 12.0% respectively.
**Gross Margin**Increased by 110 basis points to 58.6%, driven by operational improvements and pricing model changes. Adjusted gross margin was 59.4%.
**Adjusted EBITDA**Loss improved to £(86.7) million from £(117.9) million in FY24, reflecting increased gross profits and cost control.
**Cash Position**The company remains well-capitalized with £302.8 million in cash, cash equivalents, and other liquid investments.
### **Operational and Strategic Highlights**
**Market Expansion**Strong demand across priority markets, particularly in Clinical, BioPharma, and Applied Industrial segments, driven by the adoption of Oxford Nanopores technology for richer, faster data.
**Clinical Collaborations**Strategic partnerships with Cepheid and bioMérieux to develop automated infectious disease sequencing solutions and rapid tuberculosis characterization.
**Technology Advancements**Improvements in throughput, cost efficiency, and robustness, particularly for the PromethION platform, alongside enhanced basecalling and real-time methylation detection.
**Scientific Validation**Over 4,000 peer-reviewed papers published in 2025, reinforcing scientific leadership and supporting clinical and commercial adoption.
**Strategic Focus**Refinement of the operating model to prioritize high-value market opportunities, resulting in restructuring actions to streamline the portfolio and concentrate investment.
**Leadership Transition**Francis Van Parys appointed as CEO, succeeding Gordon Sanghera, who will remain as an advisor until early 2027.
### **Outlook**
**FY26 Guidance**Revenue expected to grow by 21-25% on a constant currency basis, with growth weighted toward Applied end markets. Gross margin projected at approximately 62%.
**Medium-Term Goals**Reaffirmed commitment to reach adjusted EBITDA breakeven in FY27 and become cash flow positive in FY28, supported by <mark style="background-color:yellow">above</mark>-market revenue growth and operational improvements.
### **Key Challenges and Risks**
**Market Competition**Ongoing litigation with MGI over patent and trade secret infringements, with trials set for 2027.
**Regulatory Compliance**Continued efforts to strengthen quality systems and operational processes for deeper penetration of clinical and regulated markets.
**Economic Uncertainty**Potential impact of macroeconomic conditions, supply chain disruptions, and funding pressures in key markets.
### **Conclusion**
Oxford Nanopore Technologies plc demonstrated robust growth and strategic progress in 2025, positioning itself for sustained expansion in both research and applied markets. The company’s focus on innovation, operational efficiency, and strategic partnerships underscores its commitment to long-term value creation. With a strong balance sheet and clear medium-term goals, Oxford Nanopore is well-placed to capitalize on the growing demand for its molecular sensing technology.
ONT 14:01
Oxford Nanopore Technologies Ltd
Update on legal action against MGI Australia
ONT 12:31
Oxford Nanopore Technologies Ltd
Director Declaration - John O'Higgins
ONT 15:01
Oxford Nanopore Technologies Ltd
Share Incentive Plan - Director/PDMR Shareholding

AI Crunch

Single-Ticker AI Crunch
ONT signal theatre built from scored market catalysts, automated AI forecasts, and live trigger logic.

This is the ticker-specific AI Crunch desk for Oxford Nanopore Technologies Ltd. It compresses bullish and bearish catalyst scoring, best and worst AI forecast paths, and automated buy or sell trigger logic into one cockpit so users can judge conviction without hopping across screens.

Subscription Required Bullish vs Bearish Scoring AI Forecast Stack Buy / Sell Trigger Engine Catalyst Ledger
Create Account Member Login
Subscriber Unlock
Subscribe to unlock the full ONT AI Crunch cockpit.

Subscription turns this tab into a live signal desk with bullish vs bearish machine scoring, AI forecast stack comparisons, buy and sell trigger logic, and the full catalyst ledger behind every scored catalyst row.

  • AI-scored market headlines with sentiment buckets and buzzword breakdowns.
  • Forecast leaders ranked by projected gain against current market price.
  • Advanced technical scans, AI forecast stacks, and predictive MACD inside the live stock terminal charts.
  • Single-ticker AI Crunch desks with buy or sell trigger logic and full catalyst ledgers.
  • Scored earnings shock board with predicted direction, sector pulse and catalyst narrative.
  • Fast market scan built for event-driven trading, not passive dashboards.
Subscribe to unlock the ticker-specific signal stack, sentiment gauges, forecast stage, and the full catalyst ledger for ONT on 2026-03-12.

Fundamentals Matrix

Overall Fundamentals
Signal: Pending
Capital Strength
Signal: Pending
Float Liquidity
Signal: Pending
Short Pressure
Signal: Pending
Target Setup
Signal: Pending
Market Profile
Signal: Pending
Market Cap
1062359872
Enterprise Value
1544618437
Public Float
41.49
Broker Target
199.167
Shares Out
967364692
Long Interest
82
Short Interest
18
Exchange
LSE
Currency Code
GBX
ISIN
GB00BP6S8Z30
Market
None
Sector
Personal Care, Drug and Grocery Stores
Float / Shares Ratio
-
Short vs Long Delta
-
EV / Market Cap
-

Financials Matrix

Overall Stability
Signal: Pending
Profitability
Signal: Pending
Debt & Cash
Signal: Pending
Valuation Risk
Signal: Pending
Forward Expectation
Signal: Pending
Dividend Safety
Signal: Pending
Divi Rate
-
Ex Divi
2009-01-01
Earnings Date
2026-03-02
Net Debt
-139600000.0
Cash
181100000.0
EPS
-0.15
Net Income
-145200000.0
Revenue
223900000.0
Enterprise Value
1544618437
Trailing PE
-
Forward PE
-
Price Sales TTM
4.7448
Price Book MRQ
2.2655
EV Revenue
3.7329
EV EBITDA
-8.8899

Capital Radar

Capital Regime
—
Building signal blend...
Smart Money Tilt
—
Public vs institutions
Target Conviction
—
Broker coverage pulse
Insider Pressure
—
Director + TR1 flow
Last Held Position
-
Public Hands
-
Institutions
31.9483
Institutions As Of
2025-07-29
Avg Broker Target
-
Upside Vs Price
-
Purchase Director Dealing
23
Sale Director Dealing
6
Purchase TR1
12
Sale TR1
2
Broker Coverage Rows
12
Institution Holders Tracked
3
Public Vs Institutional Ownership (3D)
Top Institution Holders (Latest Per Holder)
Director Dealing Sentiment Flow
Broker Target Bias
Signal: Pending
Capital Momentum Matrix
Broker Targets Vs Price
Aggregated Institution Weight By Holder

Short Data - Last 30 Days

Nexus Pulse Engine

Overall Buy/Sell/Hold
Signal: Pending
Technical Composite
Signal: Pending
Financial Composite
Signal: Pending
Fundamental Composite
Signal: Pending
Short Pressure
Signal: Pending
Momentum Bias
Signal: Pending

Volatility Lab

ATR(14)
Realized Vol (20d)
Volume Spike Z

AI Charts

Today's Catalysts

1 live catalyst just hit ONT.

The headlines landing in Digested News are now framed here as today's catalyst tape. Scroll the tab rail to Digested News or jump there instantly below.
Live Tape Data 2026-03-12 AI Charts Landing View
Scroll the tab rail to Digested News any time, or use the jump button to land straight on today's tape.
1 Today
Catalyst Pulse
Oxford Nanopore Technologies Ltd has fresh news flow feeding the chart narrative.
AI Charts Studio
ONT Price History
Live structure, automated forecasts, technical overlays and catalyst beacons in one chart workspace.
30 Day View Window 30D Data 2026-03-12 Open Preview Studio Brief
Chart Intelligence Suite
Swipe the timeframe, call the overlays, and keep the AI signal stack fused into one chart cockpit.
The mobile chart console is now framed as one connected surface so forecasting, structure, catalyst beacons and chart tools all sit inside the price workspace.

Automated signalling scans momentum shifts, crossovers and volatility breaks in real time. Automated AI forecasts map best, average and worst simulation paths forward, predictive MACD extends the momentum story, and catalyst beacons pin market-moving headlines directly onto price action so users can connect news, signals and structure without leaving the chart.

Automated Signalling Automated AI Forecasts Predictive MACD Catalyst Beacons Live Price Structure
TradingFloor AI Member Login
Indicators0
Technicals0
AI Forecast 17.70%
RSI Gauge
Price Change
AI Forecast